Risk of Parkinson's disease after tamoxifen treatment

BMC Neurology

Volumn 10, Issue , 2010, Pages

  Latourelle, Jeanne C ^a,b   Dybdahl, Merete ^c   Destefano, Anita L ^a,b   Myers, Richard H ^a   Lash, Timothy L ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG EFFECT; FEMALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; AGE DISTRIBUTION; BREAST TUMOR; MIDDLE AGED; RISK FACTOR;

AGE DISTRIBUTION; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS; TAMOXIFEN;

EID: 77950678852     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-10-23     Document Type: Article

References (45)

1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999, 52(6):1214-1220.
2. Mayeux R. Epidemiology of neurodegeneration. Annual review of neuroscience 2003, 26:81-104. 10.1146/annurev.neuro.26.043002.094919, 12574495.
3. Singh M, Dykens JA, Simpkins JW. Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med (Maywood) 2006, 231(5):514-521.
4. Nicoletti A, Arabia G, Pugliese P, Nicoletti G, Torchia G, Condino F, Morgante L, Quattrone A, Zappia M. Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial. Clin Neuropharmacol 2007, 30(5):276-280. 10.1097/wnf.0b013e318050c9f9, 17909305.
5. Blanchet PJ, Fang J, Hyland K, Arnold LA, Mouradian MM, Chase TN. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 1999, 53(1):91-95.
6. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 1999, 52(7):1417-1421.
7. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Archives of neurology 2004, 61(6):886-888. 10.1001/archneur.61.6.886, 15210525.
8. Ragonese P, D'Amelio M, Salemi G, Aridon P, Gammino M, Epifanio A, Morgante L, Savettieri G. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004, 62(11):2010-2014.
9. Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001, 16(5):830-837. 10.1002/mds.1170, 11746612.
10. Popat RA, Eeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, Leimpeter A, Nelson LM. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005, 65(3):383-390. 10.1212/01.wnl.0000171344.87802.94, 16087902.
11. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003, 60(5):790-795.
12. Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 2009, 24(9):1359-1365. 10.1002/mds.22619, 19424986.
13. Jordan VC, Gapstur S, Morrow M. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute 2001, 93(19):1449-1457. 10.1093/jnci/93.19.1449, 11584060.
14. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007, 25(36):5815-5824. 10.1200/JCO.2007.11.3886, 17893378.
15. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007, 8(3):229-239. 10.1007/s11154-007-9034-4, 17440819.
16. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097.
17. Payne SJ, Bowen RL, Jones JL, Wells CA. Predictive markers in breast cancer--the present. Histopathology 2008, 52(1):82-90.
18. Castellon SA, Silverman DH, Ganz PA. Breast cancer treatment and cognitive functioning: current status and future challenges in assessment. Breast Cancer Res Treat 2005, 92(3):199-206. 10.1007/s10549-005-5342-0, 16155790.
19. Sumner BE, Grant KE, Rosie R, Hegele-Hartung C, Fritzemeier KH, Fink G. Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Brain Res Mol Brain Res 1999, 73(1-2):119-128. 10.1016/S0169-328X(99)00243-0, 10581405.
20. Sumner BE, Grant KE, Rosie R, Hegele-Hartung C, Fritzemeier KH, Fink G. Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain. Neurosci Lett 2007, 417(1):95-99. 10.1016/j.neulet.2007.02.039, 17398000.
21. Callier S, Morissette M, Grandbois M, Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000, 37(4):245-251. 10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5, 10891861.
22. Grandbois M, Morissette M, Callier S, Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000, 11(2):343-346. 10.1097/00001756-200002070-00024, 10674483.
23. Dluzen DE. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. Journal of neurocytology 2000, 29(5-6):387-399. 10.1023/A:1007117424491, 11424955.
24. Dluzen DE, McDermott JL, Anderson LI. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotoxicity research 2001, 3(3):291-300. 10.1007/BF03033268, 15111254.
25. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001, 103(2):385-394. 10.1016/S0306-4522(01)00014-8, 11246153.
26. Blichert-Toft M, Christiansen P, Mouridsen HT. Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary. Acta oncologica (Stockholm, Sweden) 2008, 47(4):497-505. 10.1080/02841860802068615, 18465316.
27. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute 2006, 98(19):1406-1415.
28. Jensen AR, Storm HH, Moller S, Overgaard J. Validity and representativity in the Danish Breast Cancer Cooperative Group--a study on protocol allocation and data validity from one county to a multi-centre database. Acta oncologica (Stockholm, Sweden) 2003, 42(3):179-185. 10.1080/02841860310000737, 12852693.
29. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta oncologica (Stockholm, Sweden) 2008, 47(4):506-524. 10.1080/02841860802059259, 18465317.
30. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46(3):263-268.
31. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H. Atypical cancer pattern in patients with Parkinson's disease. British journal of cancer 2005, 92(1):201-205. 10.1038/sj.bjc.6602279, 2361753, 15583688.
32. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst Monogr 2001, (30):56-61.
33. Lewis JP. An interpretation of the EBCTCG data. Oncologist 2007, 12(5):505-509. 10.1634/theoncologist.12-5-505, 17522235.
34. Morrish PK. Parkinson's disease is not a long-latency illness. Mov Disord 1997, 12(6):849-854. 10.1002/mds.870120603, 9399205.
35. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Annals of neurology 2002, 52(3):276-284. 10.1002/ana.10277, 12205639.
36. Galanaud JP, Elbaz A, Clavel J, Vidal JS, Correze JR, Alperovitch A, Tzourio C. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure. Mov Disord 2005, 20(2):181-189. 10.1002/mds.20307, 15468111.
37. Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Rodriguez C, Thun MJ. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. American journal of epidemiology 2004, 160(10):977-984. 10.1093/aje/kwh312, 15522854.
38. Kesteloot H. Queen Margrethe II and mortality in Danish women. Lancet 2001, 357(9259):871-872. 10.1016/S0140-6736(00)04202-1, 11265968.
39. Rayner M, Petersen S. European Cardiovascular Disease Statistics. 2000, 44-52. London: British Heart Foundation.
40. Zhan M, Flaws JA, Gallicchio L, Tkaczuk K, Lewis LM, Royak-Schaler R. Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect Prev 2007, 31(5):384-390. 10.1016/j.cdp.2007.10.004, 18023540.
41. Rothman KJ, Greenland S, Lash TL. Modern epidemiology 2008, Philadelphia: Lippincott Williams & Wilkins, 3.
42. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Eeden SK, Gorell J. Pooled analysis of tobacco use and risk of Parkinson disease. Archives of neurology 2007, 64(7):990-997. 10.1001/archneur.64.7.990, 17620489.
43. Fryzek JP, Hansen J, Cohen S, Bonde JP, Llambias MT, Kolstad HA, Skytthe A, Lipworth L, Blot WJ, Olsen JH. A cohort study of Parkinson's disease and other neurodegenerative disorders in Danish welders. Journal of occupational and environmental medicine/American College of Occupational and Environmental Medicine 2005, 47(5):466-472.
44. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry 1988, 51(6):745-752. 10.1136/jnnp.51.6.745, 1033142, 2841426.
45. Brandt-Christensen M, Kvist K, Nilsson FM, Andersen PK, Kessing LV. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study. Mov Disord 2006, 21(8):1221-1225. 10.1002/mds.20907, 16671076.